<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02655354</url>
  </required_header>
  <id_info>
    <org_study_id>20150987</org_study_id>
    <secondary_id>UH3MH106338</secondary_id>
    <nct_id>NCT02655354</nct_id>
  </id_info>
  <brief_title>A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity</brief_title>
  <acronym>TSOS6</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching goal of this UH2-UH3 proposal is to work with the NIH Health Care Systems&#xD;
      Research Collaboratory to develop and implement a large scale, cluster randomized pragmatic&#xD;
      clinical trial demonstration project that directly informs national trauma care system policy&#xD;
      targeting injured patients with presentations of Posttraumatic Stress Disorder (PTSD) and&#xD;
      related comorbidity. Each year in the United States (US), over 30 million individuals present&#xD;
      to trauma centers, emergency departments, and other acute care medical settings for the&#xD;
      treatment of physical injuries. Multiple chronic conditions including enduring PTSD, alcohol&#xD;
      and drug use problems, depression and associated suicidal ideation, pain and somatic symptom&#xD;
      amplification, and chronic medical conditions (e.g., hypertension, coronary artery disease,&#xD;
      diabetes, and pulmonary diseases) are endemic among physical trauma survivors with and&#xD;
      without traumatic brain injuries (TBI). Evidence-based, collaborative care/care management&#xD;
      treatment models for PTSD and related comorbidities exist. These care management models have&#xD;
      the potential to be flexibly implemented in order to prevent the development of chronic PTSD&#xD;
      and depressive symptoms, alcohol use problems, and enduring physical disability in survivors&#xD;
      of both TBI and non-TBI injuries; care management models may also be effective in mitigating&#xD;
      the impact of the acute injury event on symptom exacerbations in the large subpopulation of&#xD;
      injury survivors who already carry a substantial pre-injury burden of multiple chronic&#xD;
      medical conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Aims and Hypotheses&#xD;
&#xD;
      The primary aim of the UH3 period is to conduct a pragmatic randomized effectiveness trial of&#xD;
      a collaborative care intervention targeting PTSD and comorbid conditions after acute care&#xD;
      injury hospitalization. The investigation aims to determine if injured patients receiving the&#xD;
      collaborative care intervention demonstrate significant reductions in PTSD symptoms when&#xD;
      compared to control patients receiving care as usual. The study also aims to determine if the&#xD;
      intervention patients when compared to control patients will demonstrate significant&#xD;
      reductions in depressive symptoms, suicidal ideation, and alcohol use problems, and&#xD;
      improvements in physical function. The primary hypothesis is that the intervention group when&#xD;
      compared to the control group will demonstrate significant reductions in PTSD symptoms over&#xD;
      the course of the year after injury. Secondary hypotheses are that intervention patients when&#xD;
      compared to control patients will demonstrate, significant reductions in depressive symptoms,&#xD;
      significant reductions in alcohol use problems, and improved post-injury physical function.&#xD;
&#xD;
      A Priori Secondary Analyses&#xD;
&#xD;
      The study team hypothesizes that a subgroup of patients will have persistent PTSD symptoms&#xD;
      that will not remit over the longitudinal course of the investigation, regardless of&#xD;
      randomization to intervention or control group conditions. The study team also anticipates&#xD;
      that readily identifiable baseline clinical, injury and demographic characteristics will be&#xD;
      associated with persistent PTSD symptoms over time (e.g., higher PTSD symptom levels, greater&#xD;
      pre-injury trauma exposure, intentional injury including firearm related injury mechanisms&#xD;
      and other characteristics such as unemployment, as well as other baseline factors). Derived&#xD;
      from previous randomized clinical trials, a cumulative burden index has been developed from&#xD;
      these baseline characteristics and will be adapted for the current investigation. The study&#xD;
      team proposes a series of secondary analyses that adjust for and stratify by baseline&#xD;
      characteristics that put patients at risk for persistent symptoms. It is hypothesized that&#xD;
      these secondary analyses will identify a subgroup of intervention patients who are not at&#xD;
      risk for persistent symptoms and who will demonstrate clinically and statistically&#xD;
      significant treatment responses when compared to patients with similar baseline&#xD;
      characteristics in the control condition. The study team also hypothesizes that the treatment&#xD;
      effects will be greatest at the 1-6 month post-injury time points that are temporally&#xD;
      correlated with the period of active intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">November 2019</completion_date>
  <primary_completion_date type="Actual">November 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline PTSD Checklist- Civilian (PCL-C) Over the Course of the Year After Injury</measure>
    <time_frame>Baseline, 3-month, 6-month, 12-month</time_frame>
    <description>The investigators will use the PTSD Checklist - Civilian (PCL-C). The scoring of the scale ranges from a minimum of 17 to a maximum of 85, with higher scores indicating a worse outcome. The measure can also provide a rating of symptoms consistent with a diagnosis of PTSD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline Patient Health Questionnaire 9 Item Depression Scale Over the Course of the Year After Injury</measure>
    <time_frame>Baseline, 3-month, 6-month, 12-month</time_frame>
    <description>The investigators will use the Patient Health Questionnaire 9-item Depression Scale (PHQ-9). The scoring of the scale ranges from a minimum of 0 to a maximum of 27, with higher scores indicating a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline Alcohol Use Disorders Identification Over the Course of the Year After Injury</measure>
    <time_frame>Baseline, 3-month, 6-month, 12-month</time_frame>
    <description>The investigators will use the Alcohol Use Disorders Identification Test (AUDIT) as a continuous measure. The 10-item scale score ranges from 0-40, with higher values indicating a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline Short Form (SF)-12/36 Physical Function Over the Course of the Year After Injury</measure>
    <time_frame>Baseline, 3-month, 6-month, 12-month</time_frame>
    <description>The investigators used the Medical Outcomes Study Short Form healthy survey (MOS SF-12/36) physical components summary to assess physical function. The minimum and maximum scores are 0-100 with higher scores representing a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Suicidal Ideation</measure>
    <time_frame>Baseline, 3-month, 6-month, 12-month</time_frame>
    <description>Item 9 of the Patient Health Questionnaire 9-item (PHQ-9) scale assesses suicidal ideation. It is scored from 0 to 3, with a score of 1 or greater indicating a patient has suicidal ideation. Participants with a PHQ-9 item 9 score of greater than or equal to 1 are reported for this outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Endorsing a Single Item That Assesses Opioid Use</measure>
    <time_frame>Baseline, 3-month, 6-month, 12-month</time_frame>
    <description>Single items that assess non-prescribed opioid use. Single item self-report dichotomized as none versus at least monthly use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Impairment Scale</measure>
    <time_frame>Baseline, 3-month, 6-month, 12-month</time_frame>
    <description>The investigators will use the National Study on the Costs and Outcomes of Trauma (NSCOT) Cognitive Screen, a 4 - Item Traumatic Brain Injury / Post-concussive Symptom Screen. The scoring of the scale ranges from a minimum of 4 to a maximum of 20, with lower scores indicating a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory</measure>
    <time_frame>Baseline, 3-month, 6-month, 12-month</time_frame>
    <description>A brief measure scored on a 0 to 10 scale to assess a patient's pain, with a higher score indicating more severe pain; a score of 0 indicates no pain and a score of 10 indicates very severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 Quality of Life</measure>
    <time_frame>Baseline, 3-month, 6-month, 12-month</time_frame>
    <description>The SF-36 assess quality of life domains that span emotional health, overall health status, and role function; a score of 100 indicates perfect health and a score of 0 indicates extremely poor health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TSOS Patient Satisfaction: Overall Health Care</measure>
    <time_frame>Baseline, 3-month, 6-month, 12-month</time_frame>
    <description>Satisfaction with health care was rated on a scale of 1 to 5, with 1 indicating very dissatisfied and 5 indicating very satisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Endorsing a Single Item That Assesses Stimulant Use</measure>
    <time_frame>Baseline, 3-month, 6-month, 12-month</time_frame>
    <description>Single items that assess non-prescribed stimulant use. Single item self-report dichotomized as none versus at least monthly use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Endorsing a Single Item That Assesses Marijuana Use</measure>
    <time_frame>Baseline, 3-month, 6-month, 12-month</time_frame>
    <description>Single items that assess marijuana use. Single item self-report dichotomized as none versus at least monthly use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TSOS Patient Satisfaction: Mental Health Care</measure>
    <time_frame>Baseline, 3 Month, 6 Month, 12 Month</time_frame>
    <description>Satisfaction with mental health care was rated on a scale of 1 to 5, with 1 indicating very dissatisfied and 5 indicating very satisfied.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">635</enrollment>
  <condition>Posttraumatic Stress Disorder</condition>
  <condition>Depression</condition>
  <condition>Alcohol-Related Disorders</condition>
  <condition>Suicidal Ideation</condition>
  <condition>Substance-Related Disorders</condition>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Quality of Life</condition>
  <condition>Pain</condition>
  <condition>Wounds and Injury</condition>
  <condition>Brain Injuries</condition>
  <condition>Chronic Disease</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both traumatic brain injury(TBI) and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, motivational interviewing, cognitive behavioral therapy elements, psychotropic drugs, and psychotherapy elements.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Enhanced standard care practices will be administered to this arm. This enhancement is sharing distressing emotional symptoms at recruitment with the attending nursing staff to address with patient subject.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Motivational Interviewing</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Behavioral Therapy Elements</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Care Management</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine</intervention_name>
    <description>Anti-depressant</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluvoxamine</intervention_name>
    <description>Anti-depressant</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine</intervention_name>
    <description>Anti-depressant</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>Anti-depressant</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram</intervention_name>
    <description>Anti-depressant</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine</intervention_name>
    <description>Anti-depressant</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Anti-depressant</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirtazapine</intervention_name>
    <description>Anti-depressant</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <description>Sleep medication</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trazodone</intervention_name>
    <description>Sleep medication</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prazosin</intervention_name>
    <description>Sleep medication</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient currently admitted to inpatient/emergency department for a traumatic injury&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-English speaking&#xD;
&#xD;
          -  Self-inflicted injury&#xD;
&#xD;
          -  Actively psychotic&#xD;
&#xD;
          -  Incarcerated or in custody&#xD;
&#xD;
          -  Less than 35 on PTSD Checklist&#xD;
&#xD;
          -  Less than 3 items on PTSD medical record screen&#xD;
&#xD;
          -  Less than 2 pieces of contact information&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas Zatzick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Honor Health</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.C. Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Clara Valley Medical Center</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.C.L.A. Harbor</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Regents</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eskenazi Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regions Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacobi Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Health Care System</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch at Galveston</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Trauma Center</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Wisconsin Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 27, 2015</study_first_submitted>
  <study_first_submitted_qc>January 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2016</study_first_posted>
  <results_first_submitted>April 20, 2021</results_first_submitted>
  <results_first_submitted_qc>July 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2021</results_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Douglas Zatzick</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Alcohol-Related Disorders</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
    <mesh_term>Suicidal Ideation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Prazosin</mesh_term>
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
    <mesh_term>Mirtazapine</mesh_term>
    <mesh_term>Trazodone</mesh_term>
    <mesh_term>Fluvoxamine</mesh_term>
    <mesh_term>Sertraline</mesh_term>
    <mesh_term>Fluoxetine</mesh_term>
    <mesh_term>Paroxetine</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT02655354/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intervention</title>
          <description>The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both traumatic brain injury(TBI) and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, motivational interviewing, cognitive behavioral therapy elements, psychotropic drugs, and psychotherapy elements.&#xD;
Motivational Interviewing&#xD;
Cognitive Behavioral Therapy Elements&#xD;
Care Management&#xD;
Fluoxetine: Anti-depressant&#xD;
Fluvoxamine: Anti-depressant&#xD;
Paroxetine: Anti-depressant&#xD;
Sertraline: Anti-depressant&#xD;
Citalopram: Anti-depressant&#xD;
Venlafaxine: Anti-depressant&#xD;
Duloxetine: Anti-depressant&#xD;
Mirtazapine: Anti-depressant&#xD;
Diphenhydramine: Sleep medication&#xD;
Trazodone: Sleep medication&#xD;
Prazosin: Sleep medication</description>
        </group>
        <group group_id="P2">
          <title>Usual Care</title>
          <description>Enhanced standard care practices will be administered to this arm. This enhancement is sharing distressing emotional symptoms at recruitment with the attending nursing staff to address with patient subject.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="265"/>
                <participants group_id="P2" count="370"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="188"/>
                <participants group_id="P2" count="289"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="81"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention</title>
          <description>The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both traumatic brain injury(TBI) and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, motivational interviewing, cognitive behavioral therapy elements, psychotropic drugs, and psychotherapy elements.&#xD;
Motivational Interviewing&#xD;
Cognitive Behavioral Therapy Elements&#xD;
Care Management&#xD;
Fluoxetine: Anti-depressant&#xD;
Fluvoxamine: Anti-depressant&#xD;
Paroxetine: Anti-depressant&#xD;
Sertraline: Anti-depressant&#xD;
Citalopram: Anti-depressant&#xD;
Venlafaxine: Anti-depressant&#xD;
Duloxetine: Anti-depressant&#xD;
Mirtazapine: Anti-depressant&#xD;
Diphenhydramine: Sleep medication&#xD;
Trazodone: Sleep medication&#xD;
Prazosin: Sleep medication</description>
        </group>
        <group group_id="B2">
          <title>Usual Care</title>
          <description>Enhanced standard care practices will be administered to this arm. This enhancement is sharing distressing emotional symptoms at recruitment with the attending nursing staff to address with patient subject.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="265"/>
            <count group_id="B2" value="370"/>
            <count group_id="B3" value="635"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.6" spread="13.4"/>
                    <measurement group_id="B2" value="39.9" spread="14.8"/>
                    <measurement group_id="B3" value="39.0" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="308"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="209"/>
                    <measurement group_id="B3" value="327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="214"/>
                    <measurement group_id="B2" value="316"/>
                    <measurement group_id="B3" value="530"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="188"/>
                    <measurement group_id="B3" value="315"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="218"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mixed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline PCL-C total score</title>
          <description>The investigators will use the PTSD Checklist - Civilian (PCL-C). The scoring of the scale ranges from a minimum of 17 to a maximum of 85, with higher scores indicating a worse outcome. The measure can also provide a rating of symptoms consistent with a diagnosis of PTSD.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.0" spread="12.6"/>
                    <measurement group_id="B2" value="50.7" spread="11.2"/>
                    <measurement group_id="B3" value="52.1" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline PTSD Checklist- Civilian (PCL-C) Over the Course of the Year After Injury</title>
        <description>The investigators will use the PTSD Checklist - Civilian (PCL-C). The scoring of the scale ranges from a minimum of 17 to a maximum of 85, with higher scores indicating a worse outcome. The measure can also provide a rating of symptoms consistent with a diagnosis of PTSD.</description>
        <time_frame>Baseline, 3-month, 6-month, 12-month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both traumatic brain injury(TBI) and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, motivational interviewing, cognitive behavioral therapy elements, psychotropic drugs, and psychotherapy elements.&#xD;
Motivational Interviewing&#xD;
Cognitive Behavioral Therapy Elements&#xD;
Care Management&#xD;
Fluoxetine: Anti-depressant&#xD;
Fluvoxamine: Anti-depressant&#xD;
Paroxetine: Anti-depressant&#xD;
Sertraline: Anti-depressant&#xD;
Citalopram: Anti-depressant&#xD;
Venlafaxine: Anti-depressant&#xD;
Duloxetine: Anti-depressant&#xD;
Mirtazapine: Anti-depressant&#xD;
Diphenhydramine: Sleep medication&#xD;
Trazodone: Sleep medication&#xD;
Prazosin: Sleep medication</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Enhanced standard care practices will be administered to this arm. This enhancement is sharing distressing emotional symptoms at recruitment with the attending nursing staff to address with patient subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline PTSD Checklist- Civilian (PCL-C) Over the Course of the Year After Injury</title>
          <description>The investigators will use the PTSD Checklist - Civilian (PCL-C). The scoring of the scale ranges from a minimum of 17 to a maximum of 85, with higher scores indicating a worse outcome. The measure can also provide a rating of symptoms consistent with a diagnosis of PTSD.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline at 3 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.65" spread="0.86"/>
                    <measurement group_id="O2" value="0.08" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at 6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.02" spread="0.99"/>
                    <measurement group_id="O2" value="-1.44" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at 12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.51" spread="1.18"/>
                    <measurement group_id="O2" value="-4.25" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline Patient Health Questionnaire 9 Item Depression Scale Over the Course of the Year After Injury</title>
        <description>The investigators will use the Patient Health Questionnaire 9-item Depression Scale (PHQ-9). The scoring of the scale ranges from a minimum of 0 to a maximum of 27, with higher scores indicating a worse outcome.</description>
        <time_frame>Baseline, 3-month, 6-month, 12-month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both traumatic brain injury(TBI) and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, motivational interviewing, cognitive behavioral therapy elements, psychotropic drugs, and psychotherapy elements.&#xD;
Motivational Interviewing&#xD;
Cognitive Behavioral Therapy Elements&#xD;
Care Management&#xD;
Fluoxetine: Anti-depressant&#xD;
Fluvoxamine: Anti-depressant&#xD;
Paroxetine: Anti-depressant&#xD;
Sertraline: Anti-depressant&#xD;
Citalopram: Anti-depressant&#xD;
Venlafaxine: Anti-depressant&#xD;
Duloxetine: Anti-depressant&#xD;
Mirtazapine: Anti-depressant&#xD;
Diphenhydramine: Sleep medication&#xD;
Trazodone: Sleep medication&#xD;
Prazosin: Sleep medication</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Enhanced standard care practices will be administered to this arm. This enhancement is sharing distressing emotional symptoms at recruitment with the attending nursing staff to address with patient subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Patient Health Questionnaire 9 Item Depression Scale Over the Course of the Year After Injury</title>
          <description>The investigators will use the Patient Health Questionnaire 9-item Depression Scale (PHQ-9). The scoring of the scale ranges from a minimum of 0 to a maximum of 27, with higher scores indicating a worse outcome.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline at 3 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" spread="0.40"/>
                    <measurement group_id="O2" value="-0.50" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at 6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.17" spread="0.45"/>
                    <measurement group_id="O2" value="-0.90" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at 12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.84" spread="0.52"/>
                    <measurement group_id="O2" value="-2.16" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline Alcohol Use Disorders Identification Over the Course of the Year After Injury</title>
        <description>The investigators will use the Alcohol Use Disorders Identification Test (AUDIT) as a continuous measure. The 10-item scale score ranges from 0-40, with higher values indicating a worse outcome.</description>
        <time_frame>Baseline, 3-month, 6-month, 12-month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both traumatic brain injury(TBI) and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, motivational interviewing, cognitive behavioral therapy elements, psychotropic drugs, and psychotherapy elements.&#xD;
Motivational Interviewing&#xD;
Cognitive Behavioral Therapy Elements&#xD;
Care Management&#xD;
Fluoxetine: Anti-depressant&#xD;
Fluvoxamine: Anti-depressant&#xD;
Paroxetine: Anti-depressant&#xD;
Sertraline: Anti-depressant&#xD;
Citalopram: Anti-depressant&#xD;
Venlafaxine: Anti-depressant&#xD;
Duloxetine: Anti-depressant&#xD;
Mirtazapine: Anti-depressant&#xD;
Diphenhydramine: Sleep medication&#xD;
Trazodone: Sleep medication&#xD;
Prazosin: Sleep medication</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Enhanced standard care practices will be administered to this arm. This enhancement is sharing distressing emotional symptoms at recruitment with the attending nursing staff to address with patient subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Alcohol Use Disorders Identification Over the Course of the Year After Injury</title>
          <description>The investigators will use the Alcohol Use Disorders Identification Test (AUDIT) as a continuous measure. The 10-item scale score ranges from 0-40, with higher values indicating a worse outcome.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline at 3 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.04" spread="0.21"/>
                    <measurement group_id="O2" value="-1.90" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at 6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.69" spread="0.22"/>
                    <measurement group_id="O2" value="-1.63" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at 12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.81" spread="0.23"/>
                    <measurement group_id="O2" value="-1.45" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline Short Form (SF)-12/36 Physical Function Over the Course of the Year After Injury</title>
        <description>The investigators used the Medical Outcomes Study Short Form healthy survey (MOS SF-12/36) physical components summary to assess physical function. The minimum and maximum scores are 0-100 with higher scores representing a better outcome.</description>
        <time_frame>Baseline, 3-month, 6-month, 12-month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both traumatic brain injury(TBI) and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, motivational interviewing, cognitive behavioral therapy elements, psychotropic drugs, and psychotherapy elements.&#xD;
Motivational Interviewing&#xD;
Cognitive Behavioral Therapy Elements&#xD;
Care Management&#xD;
Fluoxetine: Anti-depressant&#xD;
Fluvoxamine: Anti-depressant&#xD;
Paroxetine: Anti-depressant&#xD;
Sertraline: Anti-depressant&#xD;
Citalopram: Anti-depressant&#xD;
Venlafaxine: Anti-depressant&#xD;
Duloxetine: Anti-depressant&#xD;
Mirtazapine: Anti-depressant&#xD;
Diphenhydramine: Sleep medication&#xD;
Trazodone: Sleep medication&#xD;
Prazosin: Sleep medication</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Enhanced standard care practices will be administered to this arm. This enhancement is sharing distressing emotional symptoms at recruitment with the attending nursing staff to address with patient subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Short Form (SF)-12/36 Physical Function Over the Course of the Year After Injury</title>
          <description>The investigators used the Medical Outcomes Study Short Form healthy survey (MOS SF-12/36) physical components summary to assess physical function. The minimum and maximum scores are 0-100 with higher scores representing a better outcome.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline at 3 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.78" spread="0.69"/>
                    <measurement group_id="O2" value="-15.90" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at 6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.17" spread="0.79"/>
                    <measurement group_id="O2" value="-13.83" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at 12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.23" spread="0.94"/>
                    <measurement group_id="O2" value="-11.68" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Suicidal Ideation</title>
        <description>Item 9 of the Patient Health Questionnaire 9-item (PHQ-9) scale assesses suicidal ideation. It is scored from 0 to 3, with a score of 1 or greater indicating a patient has suicidal ideation. Participants with a PHQ-9 item 9 score of greater than or equal to 1 are reported for this outcome.</description>
        <time_frame>Baseline, 3-month, 6-month, 12-month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both traumatic brain injury(TBI) and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, motivational interviewing, cognitive behavioral therapy elements, psychotropic drugs, and psychotherapy elements.&#xD;
Motivational Interviewing&#xD;
Cognitive Behavioral Therapy Elements&#xD;
Care Management&#xD;
Fluoxetine: Anti-depressant&#xD;
Fluvoxamine: Anti-depressant&#xD;
Paroxetine: Anti-depressant&#xD;
Sertraline: Anti-depressant&#xD;
Citalopram: Anti-depressant&#xD;
Venlafaxine: Anti-depressant&#xD;
Duloxetine: Anti-depressant&#xD;
Mirtazapine: Anti-depressant&#xD;
Diphenhydramine: Sleep medication&#xD;
Trazodone: Sleep medication&#xD;
Prazosin: Sleep medication</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Enhanced standard care practices will be administered to this arm. This enhancement is sharing distressing emotional symptoms at recruitment with the attending nursing staff to address with patient subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Suicidal Ideation</title>
          <description>Item 9 of the Patient Health Questionnaire 9-item (PHQ-9) scale assesses suicidal ideation. It is scored from 0 to 3, with a score of 1 or greater indicating a patient has suicidal ideation. Participants with a PHQ-9 item 9 score of greater than or equal to 1 are reported for this outcome.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Endorsing a Single Item That Assesses Opioid Use</title>
        <description>Single items that assess non-prescribed opioid use. Single item self-report dichotomized as none versus at least monthly use.</description>
        <time_frame>Baseline, 3-month, 6-month, 12-month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both traumatic brain injury(TBI) and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, motivational interviewing, cognitive behavioral therapy elements, psychotropic drugs, and psychotherapy elements.&#xD;
Motivational Interviewing&#xD;
Cognitive Behavioral Therapy Elements&#xD;
Care Management&#xD;
Fluoxetine: Anti-depressant&#xD;
Fluvoxamine: Anti-depressant&#xD;
Paroxetine: Anti-depressant&#xD;
Sertraline: Anti-depressant&#xD;
Citalopram: Anti-depressant&#xD;
Venlafaxine: Anti-depressant&#xD;
Duloxetine: Anti-depressant&#xD;
Mirtazapine: Anti-depressant&#xD;
Diphenhydramine: Sleep medication&#xD;
Trazodone: Sleep medication&#xD;
Prazosin: Sleep medication</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Enhanced standard care practices will be administered to this arm. This enhancement is sharing distressing emotional symptoms at recruitment with the attending nursing staff to address with patient subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Endorsing a Single Item That Assesses Opioid Use</title>
          <description>Single items that assess non-prescribed opioid use. Single item self-report dichotomized as none versus at least monthly use.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cognitive Impairment Scale</title>
        <description>The investigators will use the National Study on the Costs and Outcomes of Trauma (NSCOT) Cognitive Screen, a 4 - Item Traumatic Brain Injury / Post-concussive Symptom Screen. The scoring of the scale ranges from a minimum of 4 to a maximum of 20, with lower scores indicating a worse outcome.</description>
        <time_frame>Baseline, 3-month, 6-month, 12-month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both traumatic brain injury(TBI) and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, motivational interviewing, cognitive behavioral therapy elements, psychotropic drugs, and psychotherapy elements.&#xD;
Motivational Interviewing&#xD;
Cognitive Behavioral Therapy Elements&#xD;
Care Management&#xD;
Fluoxetine: Anti-depressant&#xD;
Fluvoxamine: Anti-depressant&#xD;
Paroxetine: Anti-depressant&#xD;
Sertraline: Anti-depressant&#xD;
Citalopram: Anti-depressant&#xD;
Venlafaxine: Anti-depressant&#xD;
Duloxetine: Anti-depressant&#xD;
Mirtazapine: Anti-depressant&#xD;
Diphenhydramine: Sleep medication&#xD;
Trazodone: Sleep medication&#xD;
Prazosin: Sleep medication</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Enhanced standard care practices will be administered to this arm. This enhancement is sharing distressing emotional symptoms at recruitment with the attending nursing staff to address with patient subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Impairment Scale</title>
          <description>The investigators will use the National Study on the Costs and Outcomes of Trauma (NSCOT) Cognitive Screen, a 4 - Item Traumatic Brain Injury / Post-concussive Symptom Screen. The scoring of the scale ranges from a minimum of 4 to a maximum of 20, with lower scores indicating a worse outcome.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="4.6"/>
                    <measurement group_id="O2" value="13.4" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" spread="4.5"/>
                    <measurement group_id="O2" value="13.2" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" spread="4.7"/>
                    <measurement group_id="O2" value="13.4" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="4.7"/>
                    <measurement group_id="O2" value="14.2" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brief Pain Inventory</title>
        <description>A brief measure scored on a 0 to 10 scale to assess a patient's pain, with a higher score indicating more severe pain; a score of 0 indicates no pain and a score of 10 indicates very severe pain.</description>
        <time_frame>Baseline, 3-month, 6-month, 12-month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both traumatic brain injury(TBI) and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, motivational interviewing, cognitive behavioral therapy elements, psychotropic drugs, and psychotherapy elements.&#xD;
Motivational Interviewing&#xD;
Cognitive Behavioral Therapy Elements&#xD;
Care Management&#xD;
Fluoxetine: Anti-depressant&#xD;
Fluvoxamine: Anti-depressant&#xD;
Paroxetine: Anti-depressant&#xD;
Sertraline: Anti-depressant&#xD;
Citalopram: Anti-depressant&#xD;
Venlafaxine: Anti-depressant&#xD;
Duloxetine: Anti-depressant&#xD;
Mirtazapine: Anti-depressant&#xD;
Diphenhydramine: Sleep medication&#xD;
Trazodone: Sleep medication&#xD;
Prazosin: Sleep medication</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Enhanced standard care practices will be administered to this arm. This enhancement is sharing distressing emotional symptoms at recruitment with the attending nursing staff to address with patient subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Pain Inventory</title>
          <description>A brief measure scored on a 0 to 10 scale to assess a patient's pain, with a higher score indicating more severe pain; a score of 0 indicates no pain and a score of 10 indicates very severe pain.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="2.4"/>
                    <measurement group_id="O2" value="6.7" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="2.9"/>
                    <measurement group_id="O2" value="4.7" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="3.1"/>
                    <measurement group_id="O2" value="4.5" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="3.0"/>
                    <measurement group_id="O2" value="3.8" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SF-36 Quality of Life</title>
        <description>The SF-36 assess quality of life domains that span emotional health, overall health status, and role function; a score of 100 indicates perfect health and a score of 0 indicates extremely poor health.</description>
        <time_frame>Baseline, 3-month, 6-month, 12-month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both traumatic brain injury(TBI) and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, motivational interviewing, cognitive behavioral therapy elements, psychotropic drugs, and psychotherapy elements.&#xD;
Motivational Interviewing&#xD;
Cognitive Behavioral Therapy Elements&#xD;
Care Management&#xD;
Fluoxetine: Anti-depressant&#xD;
Fluvoxamine: Anti-depressant&#xD;
Paroxetine: Anti-depressant&#xD;
Sertraline: Anti-depressant&#xD;
Citalopram: Anti-depressant&#xD;
Venlafaxine: Anti-depressant&#xD;
Duloxetine: Anti-depressant&#xD;
Mirtazapine: Anti-depressant&#xD;
Diphenhydramine: Sleep medication&#xD;
Trazodone: Sleep medication&#xD;
Prazosin: Sleep medication</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Enhanced standard care practices will be administered to this arm. This enhancement is sharing distressing emotional symptoms at recruitment with the attending nursing staff to address with patient subject.</description>
          </group>
        </group_list>
        <measure>
          <title>SF-36 Quality of Life</title>
          <description>The SF-36 assess quality of life domains that span emotional health, overall health status, and role function; a score of 100 indicates perfect health and a score of 0 indicates extremely poor health.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.3" spread="13.9"/>
                    <measurement group_id="O2" value="45.1" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3" spread="12.4"/>
                    <measurement group_id="O2" value="39.1" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.4" spread="14.0"/>
                    <measurement group_id="O2" value="39.5" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2" spread="13.6"/>
                    <measurement group_id="O2" value="41.4" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TSOS Patient Satisfaction: Overall Health Care</title>
        <description>Satisfaction with health care was rated on a scale of 1 to 5, with 1 indicating very dissatisfied and 5 indicating very satisfied.</description>
        <time_frame>Baseline, 3-month, 6-month, 12-month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both traumatic brain injury(TBI) and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, motivational interviewing, cognitive behavioral therapy elements, psychotropic drugs, and psychotherapy elements.&#xD;
Motivational Interviewing&#xD;
Cognitive Behavioral Therapy Elements&#xD;
Care Management&#xD;
Fluoxetine: Anti-depressant&#xD;
Fluvoxamine: Anti-depressant&#xD;
Paroxetine: Anti-depressant&#xD;
Sertraline: Anti-depressant&#xD;
Citalopram: Anti-depressant&#xD;
Venlafaxine: Anti-depressant&#xD;
Duloxetine: Anti-depressant&#xD;
Mirtazapine: Anti-depressant&#xD;
Diphenhydramine: Sleep medication&#xD;
Trazodone: Sleep medication&#xD;
Prazosin: Sleep medication</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Enhanced standard care practices will be administered to this arm. This enhancement is sharing distressing emotional symptoms at recruitment with the attending nursing staff to address with patient subject.</description>
          </group>
        </group_list>
        <measure>
          <title>TSOS Patient Satisfaction: Overall Health Care</title>
          <description>Satisfaction with health care was rated on a scale of 1 to 5, with 1 indicating very dissatisfied and 5 indicating very satisfied.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="0.9"/>
                    <measurement group_id="O2" value="4.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="1.1"/>
                    <measurement group_id="O2" value="3.8" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="1.1"/>
                    <measurement group_id="O2" value="3.8" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="1.1"/>
                    <measurement group_id="O2" value="3.8" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Endorsing a Single Item That Assesses Stimulant Use</title>
        <description>Single items that assess non-prescribed stimulant use. Single item self-report dichotomized as none versus at least monthly use.</description>
        <time_frame>Baseline, 3-month, 6-month, 12-month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both traumatic brain injury(TBI) and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, motivational interviewing, cognitive behavioral therapy elements, psychotropic drugs, and psychotherapy elements.&#xD;
Motivational Interviewing&#xD;
Cognitive Behavioral Therapy Elements&#xD;
Care Management&#xD;
Fluoxetine: Anti-depressant&#xD;
Fluvoxamine: Anti-depressant&#xD;
Paroxetine: Anti-depressant&#xD;
Sertraline: Anti-depressant&#xD;
Citalopram: Anti-depressant&#xD;
Venlafaxine: Anti-depressant&#xD;
Duloxetine: Anti-depressant&#xD;
Mirtazapine: Anti-depressant&#xD;
Diphenhydramine: Sleep medication&#xD;
Trazodone: Sleep medication&#xD;
Prazosin: Sleep medication</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Enhanced standard care practices will be administered to this arm. This enhancement is sharing distressing emotional symptoms at recruitment with the attending nursing staff to address with patient subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Endorsing a Single Item That Assesses Stimulant Use</title>
          <description>Single items that assess non-prescribed stimulant use. Single item self-report dichotomized as none versus at least monthly use.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Endorsing a Single Item That Assesses Marijuana Use</title>
        <description>Single items that assess marijuana use. Single item self-report dichotomized as none versus at least monthly use.</description>
        <time_frame>Baseline, 3-month, 6-month, 12-month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both traumatic brain injury(TBI) and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, motivational interviewing, cognitive behavioral therapy elements, psychotropic drugs, and psychotherapy elements.&#xD;
Motivational Interviewing&#xD;
Cognitive Behavioral Therapy Elements&#xD;
Care Management&#xD;
Fluoxetine: Anti-depressant&#xD;
Fluvoxamine: Anti-depressant&#xD;
Paroxetine: Anti-depressant&#xD;
Sertraline: Anti-depressant&#xD;
Citalopram: Anti-depressant&#xD;
Venlafaxine: Anti-depressant&#xD;
Duloxetine: Anti-depressant&#xD;
Mirtazapine: Anti-depressant&#xD;
Diphenhydramine: Sleep medication&#xD;
Trazodone: Sleep medication&#xD;
Prazosin: Sleep medication</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Enhanced standard care practices will be administered to this arm. This enhancement is sharing distressing emotional symptoms at recruitment with the attending nursing staff to address with patient subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Endorsing a Single Item That Assesses Marijuana Use</title>
          <description>Single items that assess marijuana use. Single item self-report dichotomized as none versus at least monthly use.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TSOS Patient Satisfaction: Mental Health Care</title>
        <description>Satisfaction with mental health care was rated on a scale of 1 to 5, with 1 indicating very dissatisfied and 5 indicating very satisfied.</description>
        <time_frame>Baseline, 3 Month, 6 Month, 12 Month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both traumatic brain injury(TBI) and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, motivational interviewing, cognitive behavioral therapy elements, psychotropic drugs, and psychotherapy elements.&#xD;
Motivational Interviewing&#xD;
Cognitive Behavioral Therapy Elements&#xD;
Care Management&#xD;
Fluoxetine: Anti-depressant&#xD;
Fluvoxamine: Anti-depressant&#xD;
Paroxetine: Anti-depressant&#xD;
Sertraline: Anti-depressant&#xD;
Citalopram: Anti-depressant&#xD;
Venlafaxine: Anti-depressant&#xD;
Duloxetine: Anti-depressant&#xD;
Mirtazapine: Anti-depressant&#xD;
Diphenhydramine: Sleep medication&#xD;
Trazodone: Sleep medication&#xD;
Prazosin: Sleep medication</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Enhanced standard care practices will be administered to this arm. This enhancement is sharing distressing emotional symptoms at recruitment with the attending nursing staff to address with patient subject.</description>
          </group>
        </group_list>
        <measure>
          <title>TSOS Patient Satisfaction: Mental Health Care</title>
          <description>Satisfaction with mental health care was rated on a scale of 1 to 5, with 1 indicating very dissatisfied and 5 indicating very satisfied.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="1.0"/>
                    <measurement group_id="O2" value="4.0" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="1.1"/>
                    <measurement group_id="O2" value="3.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="1.1"/>
                    <measurement group_id="O2" value="3.4" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="1.1"/>
                    <measurement group_id="O2" value="3.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline, 3 Month, 6 Month, and 12 Month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intervention</title>
          <description>The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both traumatic brain injury(TBI) and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, motivational interviewing, cognitive behavioral therapy elements, psychotropic drugs, and psychotherapy elements.&#xD;
Motivational Interviewing&#xD;
Cognitive Behavioral Therapy Elements&#xD;
Care Management&#xD;
Fluoxetine: Anti-depressant&#xD;
Fluvoxamine: Anti-depressant&#xD;
Paroxetine: Anti-depressant&#xD;
Sertraline: Anti-depressant&#xD;
Citalopram: Anti-depressant&#xD;
Venlafaxine: Anti-depressant&#xD;
Duloxetine: Anti-depressant&#xD;
Mirtazapine: Anti-depressant&#xD;
Diphenhydramine: Sleep medication&#xD;
Trazodone: Sleep medication&#xD;
Prazosin: Sleep medication</description>
        </group>
        <group group_id="E2">
          <title>Usual Care</title>
          <description>Enhanced standard care practices will be administered to this arm. This enhancement is sharing distressing emotional symptoms at recruitment with the attending nursing staff to address with patient subject.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="197" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="197" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Douglas Zatzick</name_or_title>
      <organization>University of Washington School of Medicine</organization>
      <phone>206-744-6701</phone>
      <email>dzatzick@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

